10th IPF Summit

10th Anniversary Edition of the IPF Summit –
September 29 – October 1, 2026 | Boston, MA

For a decade, the IPF Summit has been the go-to, discussion-led forum uniting stakeholders across the pulmonary fibrosis ecosystem. In its 10th anniversary year, the stakes, and the opportunity, have never been higher.

Following a wave of positive Phase III readouts from leading companies including Bristol Myers Squibb, United Therapeutics, and Boehringer Ingelheim, the field has entered a new era of momentum. But with this progress comes increasing complexity. As standards of care evolve and more therapies emerge, the question is no longer can we develop treatments, but how to do so smarter, faster, and with meaningful differentiation.

The 10th IPF Summit is the only end-to-end, industry-led meeting designed to tackle this challenge head-on.

Bringing together 150+ experts across discovery, translational science, and clinical development, from organizations including Bristol Myers Squibb, United Therapeutics, Boehringer Ingelheim, Pfizer, Novartis, AbbVie, PureTech Health, Insilico Medicine, and many more, the summit offers a uniquely integrated view of the scientific, clinical, and strategic decisions shaping the next decade of IPF innovation.

Across dedicated content tracks, dive into emerging biology and novel targets to unlock new therapeutic avenues, biomarker-driven and translational strategies to generate clearer signals earlier and next-generation clinical trial design and combination approaches to succeed in an increasingly competitive landscape

New for 2026 includes a dedicated ILD & PPF Focus Day, designed to unpack the complexity of fibrotic lung diseases beyond IPF, alongside an investor panel offering insight into building conviction and demonstrating differentiated value in an evolving funding environment.
With 8+ hours of networking in an intentionally intimate setting, the summit is built for honest, high-value discussions, giving you direct access to the people shaping the future of pulmonary fibrosis drug development.

Whether you’re advancing early discovery, translating assets into the clinic, or positioning therapies in a crowded market, this is where the field aligns on what success now looks like, and how to achieve it.

Find out more about the 10th Anniversary Edition of the IPF Summit: https://ter.li/5ny4yhvk